UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Under Voltage Lock-Out Design Rules for Proper Start-Up of Energy Autonomous Systems Powered by Supercapacitors

Journal of physics. Conference series, 2013-12, Vol.476 (1), p.12121-5

2013

Volltextzugriff (PDF)

Powering a Commercial Datalogger by Energy Harvesting from Generated Aeroacoustic Noise

Journal of physics. Conference series, 2014-01, Vol.557 (1), p.12025-5

2014

Volltextzugriff (PDF)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Blood, 2023-04, Vol.141 (14), p.1675-1684

2023

Volltextzugriff (PDF)

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

Future oncology (London, England), 2024, Vol.20 (21), p.1455-1465

2024

Volltextzugriff (PDF)

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE

Hematological oncology, 2023-06, Vol.41 (S2), p.212-214

2023

Volltextzugriff (PDF)

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Blood, 2021-11, Vol.138 (Supplement 1), p.3845-3845

2021

Volltextzugriff (PDF)

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Blood, 2021-11, Vol.138 (Supplement 1), p.91-91

2021

Volltextzugriff (PDF)

SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B‐CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.171-172

2019

Volltextzugriff (PDF)

Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

Future oncology (London, England), 2024

2024

Volltextzugriff (PDF)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Blood advances, 2022-12, Vol.6 (23), p.5969-5979

2022

Volltextzugriff (PDF)

232 - Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S188-S189

2022

Volltextzugriff (PDF)

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S188-S189

2022

Volltextzugriff (PDF)

Lisocabtagene maraleucel in second-line large B-ell lymphoma: Primary analysis of phase 3 TRANSFORM study

BRITISH JOURNAL OF HAEMATOLOGY, 2023, Vol.201, p.10

2023

Volltextzugriff (PDF)

Lisocabtagene Maraleucel (Liso-cel) vs Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study

ONCOLOGY RESEARCH AND TREATMENT, 2023, Vol.46, p.272

2023

Volltextzugriff (PDF)

66 - Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S56-S57

2022

Volltextzugriff (PDF)

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S56-S57

2022

Volltextzugriff (PDF)

Phase 3 TRANSFORM study of lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, versus standard of care (SOC) as second-line therapy (2L) in patients (pt) with relapsed or refractory large B-cell lymphoma (LBCL)

ONCOLOGY RESEARCH AND TREATMENT, 2022, Vol.45 (SUPPL 2), p.194

2022

Volltextzugriff (PDF)

Reactions du phenylacetylene avec le melange anhydre acide acetique-acide perchlorique

Tetrahedron, 1980, Vol.36 (20), p.2967-2975

1980

Volltextzugriff (PDF)

Structures et propriétés diélectriques des poly(α-acétoxystyréne)s parasubstitués

Die Makromolekulare Chemie, 1985-07, Vol.186 (7), p.1519-1532

1985

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(20)
Tagungsberichte
(3)

Sprache

Englisch
(22)
Französisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Under Voltage Lock-Out Design Rules for Proper Start-Up of Energy Autonomous Systems Powered by Supercapacitors

Powering a Commercial Datalogger by Energy Harvesting from Generated Aeroacoustic Noise

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE

SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B‐CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY

Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Lisocabtagene maraleucel in second-line large B-ell lymphoma: Primary analysis of phase 3 TRANSFORM study

Lisocabtagene Maraleucel (Liso-cel) vs Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study

Phase 3 TRANSFORM study of lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, versus standard of care (SOC) as second-line therapy (2L) in patients (pt) with relapsed or refractory large B-cell lymphoma (LBCL)

Reactions du phenylacetylene avec le melange anhydre acide acetique-acide perchlorique

Structures et propriétés diélectriques des poly(α-acétoxystyréne)s parasubstitués

Suchergebnisse filtern